Galera Therapeutics Inc
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treat… Read more
Market Cap & Net Worth: Galera Therapeutics Inc (GRTX)
Galera Therapeutics Inc (PINK:GRTX) has a market capitalization of $2.14 Million ($2.14 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #35544 globally and #11581 in its home market, demonstrating a -19.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galera Therapeutics Inc's stock price $0.03 by its total outstanding shares 75462400 (75.46 Million).
Galera Therapeutics Inc Market Cap History: 2019 to 2025
Galera Therapeutics Inc's market capitalization history from 2019 to 2025. Data shows change from $993.09 Million to $2.14 Million (-67.31% CAGR).
Galera Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galera Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GRTX by Market Capitalization
Companies near Galera Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Galera Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Galera Therapeutics Inc Historical Marketcap From 2019 to 2025
Between 2019 and today, Galera Therapeutics Inc's market cap moved from $993.09 Million to $ 2.14 Million, with a yearly change of -67.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.14 Million | -24.47% |
| 2024 | $2.84 Million | -74.07% |
| 2023 | $10.94 Million | -90.27% |
| 2022 | $112.44 Million | -67.54% |
| 2021 | $346.37 Million | -55.13% |
| 2020 | $771.98 Million | -22.26% |
| 2019 | $993.09 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Galera Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.14 Million USD |
| MoneyControl | $2.14 Million USD |
| MarketWatch | $2.14 Million USD |
| marketcap.company | $2.14 Million USD |
| Reuters | $2.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.